TII
The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today launched a second iteration of its renowned large language model (LLM) – Falcon 2. Within this series, it has unveiled two groundbreaking versions: Falcon 2 11B, a more efficient and accessible LLM trained on 5.5 trillion tokens with 11 billion parameters, and Falcon 2 11B VLM, distinguished by its vision-to-language model (VLM) capabilities, which enable seamless conversion of visual inputs into textual outputs. While both models are multilingual, notably, Falcon 2 11B VLM stands out as TII's first multimodal model – and the only one currently in the top tier market that has this image-to-text conversion capability, marking a significant advancement in AI innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513516248/en/
Falcon Image Caption Generator (Photo: AETOSWire)
Tested against several prominent AI models in its class among pre-trained models, Falcon 2 11B surpasses the performance of Meta’s newly launched Llama 3 with 8 billion parameters (8B), and performs on par with Google’s Gemma 7B at first place (Falcon 2 11B: 64.28 vs Gemma 7B: 64.29), as independently verified by Hugging Face, a US-based platform hosting an objective evaluation tool and global leaderboard for open LLMs. More importantly, Falcon 2 11B and 11B VLM are both open-source, empowering developers worldwide with unrestricted access. In the near future, there are plans to broaden the Falcon 2 next-generation models, introducing a range of sizes. These models will be further enhanced with advanced machine learning capabilities like 'Mixture of Experts' (MoE), aimed at pushing their performance to even more sophisticated levels.
All of TII’s AI models released to date have consistently ranked in the top tier globally, as the most powerful open-source LLMs. The new scaled-down and versatile Falcon 2 11B models are set to give TII greater market adoption in the ever-evolving world of generative AI.
Falcon 2 11B models, equipped with multilingual capabilities, seamlessly tackle tasks in English, French, Spanish, German, Portuguese, and various other languages, enriching their versatility and magnifying their effectiveness across diverse scenarios. Falcon 2 11B VLM, a vision-to-language model, has the capability to identify and interpret images and visuals from the environment, providing a wide range of applications across industries such as healthcare, finance, e-commerce, education, and legal sectors. These applications range from document management, digital archiving, and context indexing to supporting individuals with visual impairments. Furthermore, these models can run efficiently on just one graphics processing unit (GPU), making them highly scalable, and easy to deploy and integrate into lighter infrastructures like laptops and other devices.
H.E. Faisal Al Bannai, Secretary General of ATRC and Strategic Research and Advanced Technology Affairs Advisor to the UAE President, said: "With the release of Falcon 2 11B, we've introduced the first model in the Falcon 2 series. While Falcon 2 11B has demonstrated outstanding performance, we reaffirm our commitment to the open-source movement with it, and to the Falcon Foundation. With other multimodal models soon coming to the market in various sizes, our aim is to ensure that developers and entities that value their privacy have access to one of the best AI models to enable their AI journey."
Speaking on the model, Dr. Hakim Hacid, Executive Director and Acting Chief Researcher of the AI Cross-Center Unit at TII, said: “AI is continually evolving, and developers are recognizing the myriad benefits of smaller, more efficient models. In addition to reducing computing power requirements and meeting sustainability criteria, these models offer enhanced flexibility, seamlessly integrating into edge AI infrastructure, the next emerging megatrend. Furthermore, the vision-to-language capabilities of Falcon 2 open new horizons for accessibility in AI, empowering users with transformative image to text interactions.”
The versatility of Falcon 2 11B has also led TII to consider working on more exciting GenAI innovations. Among these will be the adoption of a new type of machine learning capability known as the aforementioned ‘Mixture of Experts’. This method involves amalgamating smaller networks with distinct specializations, ensuring that the most knowledgeable domains collaborate to deliver highly sophisticated and customized responses – almost like having a team of smart helpers who each know something different and work together to predict or make decisions when needed. This approach not only improves accuracy, but it also accelerates decision-making, paving the way for more intelligent and efficient AI systems.
Falcon 2 11B is licenced under TII Falcon License 2.0, the permissive Apache 2.0-based software license which includes an acceptable use policy that promotes the responsible use of AI. More information on the new model can be found at FalconLLM.TII.ae.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513516248/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
